Overview
Portfolio
More
5 Horizons Ventures
Oklahoma City, United States
5 Horizons Ventures provides milestone‑based capital and operational expertise to clinical‑stage biotech companies, helping them move from science‑ready to trial‑ready faster. The firm aligns investors, CRO partners, and...
Portfolio
8+
Employees
5+
Founded
2022
AUM
≈ $0.0
Investment focus
Stages
Seed → Series B
Industries
BiotechnologyDigital HealthHealthcare Technology
Geographic scope
Global
Sources
5 Horizons Ventures
5 Horizons Ventures provides milestone‑based capital and operational expertise to clinical‑stage biotech companies, helping them move from science‑ready to trial‑ready faster. The firm aligns investors, CRO partners, and biotech founders to de‑risk development, preserve equity, and accelerate regulatory progress. It focuses on early‑stage, high‑impact therapies that have strong scientific validation but need structured support to reach the clinic.
Portfolio
8+
Employees
5+
Founded
2022
AUM
≈ $0.0
Stages
Seed → Series B
Industries
BiotechnologyDigital HealthHealthcare Technology
Geographic scope
Global
Sources
Showing 6 of 6 matched portfolio companies
The startup is developing epigenetic therapies using clinically validated p38 MAP kinase inhibitors and other small molecules to provide functional cures for patients with Friedreich's Ataxia. This approach aims to advance treatment options in the healthcare industry, similar to breakthroughs achieved in Cystic Fibrosis.
Funding: $500.0K
Rough estimate of the amount of funding raised
Funding: $500.0K
Rough estimate of the amount of funding raised
Kadence Bio is a clinical-stage life sciences company developing novel therapeutics for sexual and mental health conditions. The company's lead asset, KH-001, is in development as the first FDA-approved treatment for premature ejaculation. Kadence Bio also maintains a pipeline of compounds targeting various mood disorders.
Funding: $9.8M
Rough estimate of the amount of funding raised
Funding: $9.8M
Rough estimate of the amount of funding raised
This company develops therapeutics designed to enhance and protect microglia, the immune cells of the brain. Their approach utilizes generative AI and biomarker technology to address the declining debris clearance function associated with aging and neurological disease. The core value is improving brain health by restoring microglial function to clear harmful pathogens and cellular debris.
Psyence Biomedical is developing botanical psilocybin-based psychedelic medicines aimed at treating anxiety and depression in palliative care settings. The company utilizes an evidence-based approach to create safe and effective therapeutics derived from natural sources, addressing the need for improved mental health solutions in terminally ill patients.
Funding: $1.4M
Rough estimate of the amount of funding raised
Funding: $1.4M
Rough estimate of the amount of funding raised
This biopharmaceutical company develops cannabinoid active pharmaceutical ingredients (APIs) using hydrophilic conical structures that facilitate the internalization of cannabinoid molecules for neuroscience drug discovery. The company focuses on creating prescription medicines for patients with neurological diseases, leveraging its expertise in cannabinoid drug development to enhance treatment options.
Funding: $5.4M
Rough estimate of the amount of funding raised
Funding: $5.4M
Rough estimate of the amount of funding raised
TON is a decentralized blockchain platform that enables users to conduct commission-free cryptocurrency transactions directly through Telegram, utilizing its native Toncoin for network operations and digital asset management. The platform addresses the need for secure and efficient peer-to-peer crypto transfers while providing easy access to decentralized applications and services.
Funding: $54.0M
Rough estimate of the amount of funding raised
Funding: $54.0M
Rough estimate of the amount of funding raised
Showing 2 of 2 unmatched portfolio companies